

Cover Story
On Sept. 4, Jay Bhattacharya did something NIH directors rarely do: he appeared before the National Cancer Advisory Board, speaking directly with the NCI advisory board about hot-button policy changes taking place under his leadership at NIH.
Cancer Policy
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for September 2025
The National Cancer Institute approved the following clinical research studies last month.



CURRENT ISSUE



CURRENT ISSUE
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”